TITLE:
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

CONDITION:
Diabetes Mellitus, Type 2

INTERVENTION:
Valsartan 160 mg + nateglinide 60 mg

SUMMARY:

      This study is a test of the safety and effectiveness of two drugs, one for diabetes and one
      for hypertension, in keeping patients with high lab values of glucose from progressing to
      frank diabetes and developing cardiovascular complications. People in this study cannot have
      frank diabetes but are considered "borderline" based on blood tests. People in the study
      take none, one or both of the drugs and do not know which one(s) they are taking.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 50 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Adults

          -  Impaired glucose tolerance

          -  Age dependent risk factors

        Exclusion Criteria:

          -  Frank diabetes

        For detailed information, call contact person.
      
